Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geologica Closes Financing And Property Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Healthcare Biotechnology
Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and... see more

Recent & Breaking News (TSX:MSCL)

Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023

Newsfile September 20, 2023

Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services

Newsfile September 7, 2023

Satellos Expands Leadership Team with New CFO Appointment

Newsfile September 5, 2023

Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights

Newsfile August 29, 2023

TSX Venture Exchange, Satellos Bioscience Inc., View From The C-Suite

PR Newswire August 21, 2023

Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy

Newsfile August 2, 2023

Satellos Bioscience Announces Results from Its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan

Newsfile June 30, 2023

Satellos Bioscience Announces Appointment of Chief Medical Officer

Newsfile June 7, 2023

Satellos Bioscience Announces Grant of Stock Options

Newsfile June 1, 2023

Satellos Bioscience Announces 2023 Q1 Financial Results and Operational Highlights

Newsfile May 30, 2023

Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.

Newsfile May 17, 2023

Satellos Bioscience Closes $55M Financing to Support Development of its Lead Drug Candidate for Duchenne Muscular Dystrophy

Newsfile May 17, 2023

Satellos Bioscience Inc. Announces Filing of Final Short Form Prospectus for Proposed Offering of Common Shares

Newsfile May 10, 2023

IIROC Trading Resumption - MSCL

Canada NewsWire April 19, 2023

Satellos Bioscience Inc. Announces Pricing of Public Offering

Newsfile April 19, 2023

IIROC Trading Halt - MSCL

Canada NewsWire April 19, 2023

Satellos Bioscience Inc. Announces Public Offering of Common Shares

Newsfile April 18, 2023

Satellos Bioscience Announces 2022 Year End Financial Results and Operational Highlights

Newsfile March 30, 2023

Satellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible Debentures

Newsfile March 29, 2023

Satellos Bioscience Announces Upsize of Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures to up to $2.385 Million

Newsfile March 22, 2023